Histology
Basal Cell Carcinoma
CI-CAN-00000479Explore in graph →
57 active trials4 approved drugs6 evidence items
Loading cancer entity…
Histology
CI-CAN-00000479Explore in graph →
Clinical trials
361 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (25)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04155190 | A Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC | terminated | Phase 2 | 50 | Sol-Gel Technologies, Ltd.INDUSTRY | 1 | Jul 21, 2026 | clinicaltrials |
| NCT04916002 | A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer | terminated | Phase 2 | 77 | Regeneron PharmaceuticalsINDUSTRY | 2 | Jun 9, 2026 |
| clinicaltrials |
| NCT04410874 | Imvamune Vaccine for the Treatment of Non-melanoma Skin Cancer(MUSIC-01) | terminated | Phase 1 / Phase 2 | 1 | Ivan LitvinovOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT02956889 | To Assess The Efficacy And Safety Of Vismodegib And Radiotherapy In Advanced Basal Cell Carcinoma(virgilio) | terminated | Phase 2 | 14 | Istituto Clinico HumanitasOTHER | 1 | Jan 29, 2020 | clinicaltrials |
| NCT02067104 | Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention | terminated | Phase 2 | 9 | University of ArizonaOTHER | 1 | Aug 14, 2019 | clinicaltrials |
| NCT02303041 | Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma | terminated | Phase 2 | 10 | Anne ChangOTHER | 1 | Jan 29, 2019 | clinicaltrials |
| NCT01898598 | A Study of Vismodegib With Surgery in Participants With Previously Untreated Basal Cell Carcinoma | terminated | Phase 2 | 18 | Hoffmann-La RocheINDUSTRY | 1 | May 8, 2017 | clinicaltrials |
| NCT01808950 | Efficacy and Safety Trial of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma | terminated | Phase 1 / Phase 2 | 4 | Spirig Pharma Ltd.INDUSTRY | 2 | Jun 22, 2016 | clinicaltrials |
| NCT02059252 | Safety, Tolerability and Performance of SmartMatrix Dermal Replacement Scaffold | terminated | Phase 1 / Phase 2 | 5 | Smart Matrix LimitedOTHER | 1 | Apr 4, 2016 | clinicaltrials |
| NCT01033019 | To Evaluate the Safety, Local Tolerability, PK and PD of LDE225 on Sporadic Superficial and Nodular Skin Basal Cell Carcinomas (sBCC) | terminated | Phase 2 | 25 | Novartis PharmaceuticalsINDUSTRY | 2 | Oct 30, 2015 | clinicaltrials |
Data updated 22 days agoSource updated Jul 21, 2026source: clinicaltrials